Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma

Molecular Oncology
R D RasmussenP Hamerlik

Abstract

Recent clinical trials have demonstrated that targeting chromatin remodeling factors is as a promising strategy for the treatment of glioblastoma (GBM). We and others have shown constitutive activation of DNA damage response (DDR) pathways in gliomas and suggested that targeting the DDR may improve the currently grim prognosis for patients. Based on our previous findings that inhibition of poly(ADP-ribose) polymerase (PARP) increases radio-sensitivity of the notoriously radio-resistant GBM cells, we hypothesized that epigenetic down-regulation of the DDR responses and induction of oxidative stress via HDAC inhibition would contribute to more efficient targeting of this deadly disease. Our data show that SAHA, an HDAC class I + II inhibitor, in combination with olaparib (PARP inhibitor): i) enhanced inhibition of GBM cell survival, ii) induced apoptosis, and iii) impaired cell cycle progression. These results provide a pre-clinical rationale for combined administration of SAHA and olaparib, which are already individually in clinical trials.

References

Feb 1, 1992·Experimental Cell Research·P L OliveJ P Banáth
Mar 1, 1988·Experimental Cell Research·N P SinghE L Schneider
Feb 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emma HocklyGillian P Bates
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 29, 2005·Journal of Neurochemistry·Ilker Y EyüpogluIngmar Blümcke
May 17, 2005·Pigment Cell Research·Glen M BoylePeter G Parsons
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dong YinH Phillip Koeffler
Apr 28, 2007·Expert Opinion on Investigational Drugs·Walid K RasheedH Miles Prince
Dec 22, 2007·Science·Anja GrothGeneviève Almouzni
Oct 29, 2008·International Journal of Radiation Oncology, Biology, Physics·Fiona A DungeyAnthony J Chalmers
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evanthia GalanisJan C Buckner
Jan 6, 2010·EMBO Molecular Medicine·Ana M Mendes-PereiraAlan Ashworth
Nov 6, 2010·Journal of Neuro-oncology·Marc C Chamberlain
Jan 5, 2011·Protein & Cell·Jiaxue WuXiaochun Yu
Mar 30, 2011·Glia·Jason T HuseCameron W Brennan
May 21, 2011·Journal of Neuro-oncology·Jihong XuVinay K Puduvalli
Jun 10, 2011·Neuro-oncology·Melissa M SinghJoya Chandra
Jul 12, 2011·Nature Methods·Michael T CertoAndrew M Scharenberg
May 19, 2012·Journal of Hematology & Oncology·Salvia JainOwen O'Connor
Jun 8, 2012·The Oncologist·Georgios Rigakos, Evangelia Razis
Nov 28, 2012·Nature Reviews. Clinical Oncology·Shota TanakaJorg Dietrich
Oct 24, 2014·Annual Review of Medicine·Christopher J LordAlan Ashworth
Mar 22, 2015·Neuro-oncology·Melissa M SinghJoya Chandra
Jun 2, 2015·Expert Review of Neurotherapeutics·Brenda AuffingerMaciej S Lesniak

❮ Previous
Next ❯

Citations

Oct 22, 2016·Cellular Oncology (Dordrecht)·Mikkel StabergPetra Hamerlik
Jun 5, 2019·Current Topics in Medicinal Chemistry·Haiying LuJianyou Shi
Jan 19, 2017·Oncotarget·Dong Hoon LeeSo Hee Kwon
Sep 12, 2018·Cancers·Ying ZhangRoger Abounader
Jul 20, 2020·Journal of Experimental & Clinical Cancer Research : CR·Rui ChenYali Wang
Sep 20, 2020·Nature Communications·Elisabeth Anne Adanma ObaraPetra Hamerlik
Oct 5, 2018·Journal of Experimental & Clinical Cancer Research : CR·Wei MengJie Ma
Mar 1, 2020·International Journal of Molecular Sciences·Henriette PedersenPetra Hamerlik
Oct 4, 2020·Cancers·Henriette PedersenPetra Hamerlik
Oct 14, 2020·Cell Biology International·S Daisy PrecillaAnitha Thirugnanasambandhar Sivasubramanian
Mar 30, 2018·Molecular Cancer Research : MCR·Steven T SizemoreFen Xia
Nov 5, 2020·Pharmacology & Therapeutics·Elena KunadisChristina Piperi
May 10, 2021·Bioorganic Chemistry·Xiuhong WeiFengyuan Che
Jun 26, 2021·Pharmacology & Therapeutics·Fengchao LangChunzhang Yang
Jun 26, 2021·Journal of Experimental & Clinical Cancer Research : CR·Yali WangYanmei Zou
Mar 18, 2019·Biochemical Pharmacology·Rosângela Mayer GonçalvesAlfeu Zanotto-Filho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis